secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001601830-23-000068
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion posts Q3 net loss $93M, inks $160M Tempus data deal, restructures Bayer collaboration for oncology
--------------------------------------------------------------------------------

- Q3 net loss of $93.0M vs $60.4M prior year; revenue $10.5M down from $13.2M.
- Tempus 5-year data licensing deal: annual payments $22M-$42M (up to $160M total) for 20+ PB oncology data.
- Bayer collaboration refocused on oncology; up to 7 programs with aggregate milestones up to $1.5B plus royalties.
- BioHive-1 supercomputer to quadruple compute with NVIDIA H100 GPUs, expected top 50 globally by H1 2024.
- Cash $387.3M at Sept 30; pipeline on track with Phase 2 CCM and NF2 data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/rxrx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer